3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
Methods
2
pomalidomide
1
fasudil
1
XENP 1595
1
UE2343
1
Transurethral Resection of Bladder
1
Telemedicine
1
Surgical Procedures, Operative
1
Standard of Care
1
Hormones
1
Exercise
1
Ethanol
1
Electroencephalography
1
Drug Delivery Systems
1
Dexamethasone
1
Control Groups
1
Amputation, Surgical
1
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Alzheimer Disease
×
UE2343
×
1 year
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled